CNCR Loncar Cancer Immunotherapy ETF

*Unless otherwise stated, data provided by FactSet.

CNCR Fund Description

CNCR tracks an equal-weighted index of companies currently producing or in clinical trials for cancer immunotherapy drugs.

CNCR Factset Analytics Insight

CNCR takes an approach to niche coverage within the health care sector. It provides equal-weighted exposure to about 30 companies of various sizes that have approved immunotherapy cancer drugs on the US or European markets or that are engaged in human clinical trials of such drugs. The fund seeks a holistic exposure to the immunotherapy space, specifically including companies with varying drug mechanisms. Equal-weighting of the securities draws attention to smaller companies with room to grow. This fund provides a unique option for investors placing a highly specialized bet on this space.

PERFORMANCE [as of 09/22/22] 1 MONTH 3 MONTHS YTD 1 YEAR 3 YEARS 5 YEARS 10 YEARS
CNCR -11.04% -1.21% -39.15% -50.22% -8.11% -9.41% --
CNCR (NAV) -10.28% -1.53% -38.97% -50.14% -8.15% -9.40% --
Loncar Cancer Immunotherapy Index -- -- -- -- -- -- --
MSCI USA IMI / Pharmaceuticals Biotechnology & Life Sciences -IG -- -- -- -- -- -- --
All returns over 1 year are annualized. All returns are total returns unless otherwise stated.

CNCR Summary Data

Loncar
10/13/15
Open-Ended Fund
0.79%
$22.03M
$49.99K
0.54%

CNCR Portfolio Data

$26.10B
-14.17
2.94
12.81%
N/A
32

CNCR Index Data

Equal
Market Cap
MSCI USA IMI / Pharmaceuticals Biotechnology & Life Sciences -IG

CNCR Portfolio Management

0.79%
--
--
--

CNCR Tax Exposures

20.00% / 39.60%
--
Qualified dividends
No

CNCR Fund Structure

Open-Ended Fund
No
No
-- / --
N/A
N/A
High
Daily

CNCR Factset Analytics Block Liquidity

As of 09/23/22
5
4
3
2
1

This measurement shows how easy it is to trade a $1 million USD block of CNCR. CNCR is rated a 3 out of 5.

CNCR Tradability

3,034
$49.99K
1,797
$28.93K
0.54%
$0.09
0.02%
2.47% / -3.38%
None
100.00%
50,000
0.04
0.01%
0.37%
0
$14.47
3

CNCR Sector/Industry Breakdown


CNCR
Segment Benchmark
97.97%
--
1.87%
--
0.14%
--
0.01%
--

CNCR Top 10 Holdings[View All]

4.46%
Xencor, Inc. 3.75%
40.19%

CNCR Countries


CNCR
Segment Benchmark
73.03%
--
7.33%
--
6.06%
--
3.60%
--
3.44%
--
3.35%
--
2.96%
--

CNCR Regions


CNCR
Segment Benchmark
73.03%
--
17.24%
--
9.50%
--

CNCR Economic Development


CNCR
Segment Benchmark
93.72%
--
6.06%
--

CNCR Performance Statistics

--
--
--
--
--
MSCI USA IMI / Pharmaceuticals Biotechnology & Life Sciences -IG

CNCR Benchmark Comparison Holdings

32
--
--
--

CNCR Benchmark Comparison Summary


CNCR
Segment Benchmark
32
--
$26.10B
--
-14.17
--
2.94
--
0.37%
--
Medium
--

CNCR Benchmark Comparison Market Cap Size


CNCR
Segment Benchmark
27.96%
--
10.82%
--
59.03%
--
2.01%
--